Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. (Q40470791)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. |
scientific article |
Statements
1 reference
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. (English)
1 reference
Alain C Mita
1 reference
Lisa A Hammond
1 reference
Peter L Bonate
1 reference
Geoffrey Weiss
1 reference
Heather McCreery
1 reference
Samira Syed
1 reference
Mitchell Garrison
1 reference
Quincy S C Chu
1 reference
Johann S DeBono
1 reference
Christopher B Jones
1 reference
Steve Weitman
1 reference
Eric K Rowinsky
1 reference
1 September 2006
1 reference
1 reference
Identifiers
1 reference